NCT05671991View on ClinicalTrials.gov

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
End Stage Renal Disease on Dialysis
Interventions
DRUG

Empagliflozin 25 mg vs Placebo

Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7

DRUG

Empagliflozin 10 MG

Chronic Study- Empagliflozin 10 mg for 8 weeks

Trial Locations (1)

06510

RECRUITING

Yale University, New Haven

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Yale University

OTHER

NCT05671991 - Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease | Biotech Hunter | Biotech Hunter